Choosing uPAR to target both GBM cancer cells and the associated uPAR-positive tumor neovasculature seemed advantageous, potentially enhancing the therapeutic efficacy by depriving the growing tumor of its essential nutrient supplying source [180]. This evidence concerns the gene PLAUR and cancer.